

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Corrected copy

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated August 31, 2012,
1. Covance Clinical Research Unit, Inc. Global Clinical Pharmacology	3. License number 13-26640-01 is amended in its entirety to read as follows:
2. Covance - Evansville 617 Oakley Street Evansville, IN 47710	4. Expiration date January 31, 2016
	5. Docket No. 030-33820 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	3. Maximum amount that licensee may possess at any one time under this license
A. Carbon 14, as permitted by 10 CFR 35.100	A. Any	A. 90 millicuries
B. Hydrogen-3, as permitted by 10 CFR 35.100	B. Any	B. 90 millicuries

9. Authorized use:

Byproduct Materials Standby – NO OPERATIONS

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 617 Oakley Street, Evansville, Indiana.
11. The Radiation Safety Officer for this license is Robert G. Kochan, Ph.D.
12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for the material and medical uses indicated:

Randall R. Stoltz, M.D.	10 CFR 35.100
-------------------------	---------------
13. The licensee shall possess and use byproduct material for human research use in accordance with the prescriptive and performance criteria in all sections of 10 CFR Part 35.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-26640-01Docket or Reference Number
030-33820Amendment No. 15
Corrected copy

14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive materials."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Applications dated January 11, 2006, December 5, 2006, and February 1, 2008 with attachments (excluding all references to "Any" chemical/physical form for carbon-14 and hydrogen-3 possession and use outside of 10 CFR 35.100 authorization); and
- B. Letters dated March 1, 2007 (with attachments), February 1, 2008, March 11, 2010 and **August 31, 2012.**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

JAN 03 2013

By

Toye L. Simmons
Materials Licensing Branch
Region III